BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 247 filers reported holding BRIDGEBIO PHARMA INC in Q1 2024. The put-call ratio across all filers is 0.35 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $676,032 | -33.3% | 26,689 | -18.6% | 0.00% | – |
| Q1 2024 | $1,014,207 | -30.9% | 32,801 | -9.8% | 0.00% | -100.0% |
| Q4 2023 | $1,467,813 | +90.3% | 36,359 | +24.3% | 0.00% | – |
| Q3 2023 | $771,428 | +111.9% | 29,254 | +38.2% | 0.00% | – |
| Q2 2023 | $364,021 | +5.9% | 21,164 | +2.1% | 0.00% | – |
| Q1 2023 | $343,654 | +271.7% | 20,727 | +70.8% | 0.00% | – |
| Q4 2022 | $92,446 | -24.8% | 12,132 | -2.0% | 0.00% | – |
| Q3 2022 | $123,000 | – | 12,381 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $373,797,000 | 67.28% |
| Darwin Global Management, Ltd. | 2,090,149 | $128,753,000 | 25.21% |
| Affinity Asset Advisors, LLC | 577,500 | $35,574,000 | 12.08% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $1,913,356,000 | 9.64% |
| Perceptive Advisors | 7,756,928 | $477,827,000 | 6.04% |
| Opaleye Management Inc. | 583,767 | $35,960,000 | 5.28% |
| MIZUHO MARKETS AMERICAS LLC | 171,923 | $10,590,000 | 4.93% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $1,639,853,000 | 4.88% |
| Fernwood Investment Management, LLC | 151,085 | $9,307,000 | 3.42% |
| HHLR ADVISORS, LTD. | 5,362,014 | $330,300,000 | 3.26% |